IP Library Granted Patent US 10,647,774
Granted Patent B2
US 10,647,774 · App. 15/436,583 · Granted May 12, 2020

Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof

Inventors: Claudine Brigitte Fernande Vermot-Desroches (Dardilly, FR); Olivier Frédéric Subiger (Belleville sur Saone, FR); Laurence Françoise Jeanne-Marie Bourdin (Ecully, FR)
Assignee: GENMAB B.V.
C07K16/2878A61K2039/507C07K2317/24C07K2317/31C07K2317/35C07K2317/54C07K2317/55C07K2317/56C07K2317/565C07K2317/569C07K2317/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,647,774
App. No.
15/436,583
Granted
May 12, 2020
Kind
B2
Abstract

Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.

Claims (13)

1. An isolated nucleic acid encoding a variable light (VL) region or a variable heavy (VH) region of an antibody capable of binding a DR5 receptor, wherein the isolated nucleic acid encoding the VL region comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 1, 5, 36, and 40, and the isolated nucleic acid encoding the VH region comprises a nucleotide sequence selected from the group consisting of SEQ ID NO: 3, 7, 34, and 38.

2. An expression vector comprising the isolated nucleic acid encoding the VL region, the isolated nucleic acid encoding the VH region, or the isolated nucleic acid encoding the VL region and the isolated nucleic acid encoding the VH region according to claim 1 .

3. A host cell comprising the vector according to claim 2 .

4. A method of producing an antibody capable of binding a DR5 receptor, the method comprising

culturing the host cell of claim 3 in a culture medium under conditions sufficient to produce the antibody, wherein the host cell comprises the isolated nucleic acid encoding the VL region selected from the group consisting of SEQ ID NO: 1 and 36, and the isolated nucleic acid encoding the VH region selected from the group consisting of SEQ ID NO: 3 and 34, and

isolating the antibody from the culture medium, thereby producing the antibody capable of binding a DR5 receptor.

5. The method of claim 4 , wherein the isolated nucleic acid encoding the VL region comprises the nucleotide sequence set forth in SEQ ID NO: 1, and the isolated nucleic acid encoding the VH region comprises the nucleotide sequence set forth in SEQ ID NO: 3.

6. The method of claim 4 , wherein the isolated nucleic acid encoding the VL region comprises the nucleotide sequence set forth in SEQ ID NO: 36, and the isolated nucleic acid encoding the VH region comprises the nucleotide sequence set forth in SEQ ID NO: 34.

7. A method of producing an antibody capable of binding a DR5 receptor, the method comprising

culturing the host cell of claim 3 in a culture medium under conditions sufficient to produce the antibody, wherein the host cell comprises the isolated nucleic acid encoding the VL region selected from the group consisting of SEQ ID NO: 5 and 40, and the isolated nucleic acid encoding the VH region selected from the group consisting of SEQ ID NO: 7 and 38, and

isolating the antibody from the culture medium, thereby producing the antibody capable of binding a DR5 receptor.

8. The method of claim 7 , wherein the isolated nucleic acid encoding the VL region comprises the nucleotide sequence set forth in SEQ ID NO: 5, and the isolated nucleic acid encoding the VH region comprises the nucleotide sequence set forth in SEQ ID NO: 7.

9. The method of claim 7 , wherein the isolated nucleic acid encoding the VL region comprises the nucleotide sequence set forth in SEQ ID NO: 40, and the isolated nucleic acid encoding the VH region comprises the nucleotide sequence set forth in SEQ ID NO: 38.

Assignments (5)
SECURITY INTEREST Recorded Dec 15, 2025
From: GENMAB A/S; GENMAB B.V.; GENMAB HOLDING B.V.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 073933/0597 →
NOTICE OF GRANT OF SECURITY INTEREST IN PATENTS Recorded Dec 15, 2025
From: GENMAB HOLDING B.V.; GENMAB A/S; GENMAB B.V.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 073949/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2017
From: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH
To: GENMAB HOLDING B.V.
Reel/Frame 043032/0217 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2017
From: GENMAB HOLDING B.V.
To: GENMAB B.V.
Reel/Frame 043032/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 18, 2017
From: VERMOT-DESROCHES, CLAUDINE BRIGITTE FERNANDE; SUBIGER, OLIVIER FRÉDÉRIC; BOURDIN, LAURENCE FRANCOISE JEANNE-MARIE
To: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH
Reel/Frame 043226/0126 →